NYSEMKT: LCTX
Lineage Cell Therapeutics Inc Stock Ownership - Who owns Lineage Cell Therapeutics?

Insider buying vs selling

Have Lineage Cell Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Deborah J. AndrewsDirector2026-11-1625,000$0.80
$20.00kBuy
Brian M. CulleyCEO;Pres2026-11-1640,500$0.92
$37.10kBuy
Jill Ann HoweCFO2026-11-1620,000$0.86
$17.10kBuy
Brian M. CulleyPresident and CEO2026-03-1215,000$1.63
$24.38kBuy
George A. Samuel IiiGeneral Counsel and Secretary2026-02-112,502$1.80
$4.50kSell
Brian M. CulleyPresident and CEO2026-02-1112,869$1.80
$23.16kSell
George A. Samuel IiiGeneral Counsel and Secretary2025-12-1965$1.68
$109.20Sell
Brian M. CulleyPresident and CEO2025-12-19334$1.68
$561.12Sell

1 of 1

LCTX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when LCTX insiders and whales buy or sell their stock.

LCTX Shareholders

What type of owners hold Lineage Cell Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Broadwood Partners LP32.23%81,531,259$64.82MInsider
Neal C. Bradsher18.78%47,515,269$37.77MInsider
Alfred D. Kingsley4.09%10,344,637$8.22MInsider
George Karfunkel1.97%4,982,217$3.96MInsider
Gary K. Duberstein1.02%2,590,408$2.06MInsider
Greenbelt Corp0.41%1,043,346$829.46kInsider
Michael D. West0.35%893,913$710.66kInsider
Judith Segall0.23%591,245$470.04kInsider
Greenway Partners L P0.15%375,351$298.40kInsider
Robert Peabody0.12%315,777$251.04kInsider

1 of 3

LCTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
LCTX0.02%60.41%Net BuyingNet Buying
CYPH0.02%99.98%Net BuyingNet Buying
NGEN0.01%0.00%
VOGX0.05%33.97%Net Buying
ACIU0.02%4.42%Net Selling

Lineage Cell Therapeutics Stock Ownership FAQ

Who owns Lineage Cell Therapeutics?

Lineage Cell Therapeutics (NYSEMKT: LCTX) is owned by 0.02% institutional shareholders, 60.41% Lineage Cell Therapeutics insiders, and 39.57% retail investors. Broadwood Partners LP is the largest individual Lineage Cell Therapeutics shareholder, owning 81.53M shares representing 32.23% of the company. Broadwood Partners LP's Lineage Cell Therapeutics shares are currently valued at $66.53M.

If you're new to stock investing, here's how to buy Lineage Cell Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.